Who
Akshay Vaishnaw
President of R&D
Company insider
Files Form 4 as: President of R&D, Scholar Rock Holding; Director, Editas Medicine; President, Alnylam Pharmaceuticals.
In numbers
- Trades disclosed
- 338
- Buys
- 0
- Sells
- 39
- Bought
- $0
- Sold
- $58.8M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 10 Dec 2009
- Last trade
- 16 Apr 2026
- Last filed
- 20 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Apr 2026filed 20 Apr 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $607K12,246 at $49.57 | filing |
| 16 Apr 2026filed 20 Apr 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $607K12,246 at $49.57 | filing |
| 9 Feb 2026filed 11 Feb 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code A | —47,021 at $0.00 | filing |
| 9 Feb 2026filed 11 Feb 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code A | —47,021 at $0.00 | filing |
| 13 Jan 2026filed 15 Jan 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $873K20,438 at $42.70 | filing |
| 13 Jan 2026filed 15 Jan 2026 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $873K20,438 at $42.70 | filing |
| 29 May 2025filed 30 May 2025 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $152K5,130 at $29.63 | filing |
| 29 May 2025filed 30 May 2025 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Sold | $49K1,620 at $30.01 | filing |
| 2 May 2025filed 6 May 2025 | SRRK Scholar Rock Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,067 at $0.00 | filing |
| 27 Apr 2025filed 29 Apr 2025 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 27 Apr 2025filed 29 Apr 2025 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 27 Jun 2024filed 1 Jul 2024 | SRRK Scholar Rock Holdingoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 27 Jun 2024filed 1 Jul 2024 | SRRK Scholar Rock HoldingBiotechnology | SEC FORM 4 Code A | —13,500 at $0.00 | filing |
| 30 May 2024filed 3 Jun 2024 | EDIT Editas Medicineoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 4 Aug 2023filed 7 Aug 2023 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $142K771 at $184.70 | filing |
| 4 Aug 2023filed 7 Aug 2023 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $347K1,869 at $185.54 | filing |
| 4 Aug 2023filed 7 Aug 2023 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $206K1,107 at $186.39 | filing |
| 4 Aug 2023filed 7 Aug 2023 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $19K101 at $187.37 | filing |
| 4 Aug 2023filed 7 Aug 2023 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $3,20317 at $188.40 | filing |
| 4 Aug 2023filed 7 Aug 2023 | ALNY Alnylam PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $36K192 at $189.31 | filing |
News
Scholar Rock Resubmits Marketing Authorisation Application For ApitegromabSRRK · rttnews.com · 8 Oct 2026
0 headlines in the last 90 days name Akshay Vaishnaw; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.